Skylar Jeremias

A narrative review found obesity independently worsens psoriasis severity and blunts response to fixed-dose biologics, prompting calls for weight-adapted treatment selection.

A retrospective study of 76 patients at a Spanish allergy clinic found occupational exposure suspected in more than half of chronic hand eczema cases, with patch testing tying most sensitizations to preservatives, nickel, and rubber accelerants.

Brittany G. Craiglow, MD, FAAD, discusses JAK inhibitor hesitancy in pediatric alopecia areata, boxed warnings, and why step therapy falls short.

A review argues lung cancer screening should move beyond smoking history to include environmental exposures, family history, and AI-driven risk models, citing Taiwan's TALENT cohort as evidence broader eligibility finds cancer earlier.

Brittany G. Craiglow, MD, FAAD, discusses the psychiatric and psychosocial toll of alopecia in children and adolescents, and its impact on treatment initiation.

Paricalcitol shows more consistent parathyroid hormone control and a stronger survival signal than calcitriol in chronic kidney disease, though evidence for hard outcomes remains limited.

In the DELTA TEEN trial, 64% of adolescents with moderate to severe chronic hand eczema achieved clear or almost clear skin with delgocitinib cream versus 29% on vehicle, with mostly mild adverse events and no safety signals.

A budget impact model projects that covering delgocitinib cream for moderate to severe chronic hand eczema could save a hypothetical US health plan $87.8 million over 3 years, driven mostly by lower drug costs.

A new review argues that bulevirtide is unlikely to succeed as a stand-alone treatment and calls for combination regimens that restore antiviral immunity.

A dermatology review proposes sorting patients with overlapping atopic dermatitis and alopecia areata into 3 immunophenotype-guided archetypes to select and sequence systemic therapy.

A Lancet Neurology review detailed how Epstein-Barr virus reprograms B cells to trigger multiple sclerosis in genetically susceptible carriers, and outlined the prophylactic vaccines, therapeutic vaccines, antivirals, and T-cell therapies now in clinical testing to interrupt that process.

A Boston population health roundtable examined why patients with atopic dermatitis often stayed undertreated despite an expanding set of therapeutics.

CAR T-cell therapy shows early promise for refractory myasthenia gravis, improving symptoms with mild adverse effects as larger trials loom.

AHSCT resets the immune system in highly active RRMS after high-efficacy drugs fail, delivering higher NEDA, fewer relapses, and durable function gains.

Smartphone remote monitoring captures between-visit symptom changes in myasthenia gravis, spotting week-to-week swings and enabling earlier symptom management than clinic visits.

New study validates CVI Range-CR for measuring real-world vision in kids with cerebral visual impairment and tracking change over time.

Early multiple sclerosis symptoms may start years before relapse, as genetic markers of MS, MRI changes, and neurofilament rise reveal hidden signs of MS.

JAK inhibitors are reshaping alopecia areata care, while global registries aim to address long-term safety and effectiveness data gaps.

New review finds psoriasis biologics generally preserve kidney function, with IL-17 inhibitors showing potential renal benefits.

Topical delgocitinib in chronic hand eczema improves clearance and itch fast, with placebo-like safety.

A multidisciplinary Philadelphia roundtable surfaced the structural barriers that keep people with AD from reaching effective therapy.

Structured CHE diagnosis improves outcomes: a multicenter CRF clarifies causes for most patients with chronic hand eczema, addressing diagnosis challenges and guiding targeted care.

New formulations make topical retinoids for acne vulgaris and scarring more tolerable and effective, with promising data for trifarotene, tretinoin combinations, and retinols for acne.

Canadian dermatologists propose treat-to-target benchmarks for chronic hand eczema, pairing IGA-CHE and itch scores to guide therapy and follow-up.

Spanish dermatology consensus guides alopecia areata treatment escalation, highlighting JAK inhibitors, SALT-based staging, special-population care, and essential screening requirements.

The FDA's first new sunscreen ingredient approved in nearly 3 decades is set to reshape the US market. Here is what dermatologists need to know.

Dermatomyositis flares often match objective disease activity, with rash, weakness and fatigue as key signals; most flares don’t predict cancer.

New evidence links oxidative stress to vitiligo autoimmunity, highlighting antioxidant plus phototherapy or JAK combinations for better repigmentation.

A review finds diet, micronutrients, aerobic exercise, and mental health screening complement psoriasis treatment, lowering severity and comorbidity risk.

Alopecia areata shapes how people work, learn, and see themselves, a new occupational review finds, with barriers reaching far beyond hair loss.